Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Daiichi Sankyo Seeks FDA Approval Of WelChol With Zetia

This article was originally published in The Pink Sheet Daily

Executive Summary

Japanese firm files data with FDA showing efficacy of WelChol with ezetimibe in reducing LDL cholesterol.

You may also be interested in...



Daiichi Sankyo Eyes U.S. Expansion With Major Sales Force Boost

The Japanese pharma looks to more than double existing U.S. sales force in anticipation of rapid growth.

Daiichi Sankyo Submits WelChol sNDA For Diabetes Indication

If approved, WelChol would be the first LDL-lowering therapy also approved for improving glycemic control.

Metsera Launches As New Obesity Contender Flush With $290m

Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture. 

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS065821

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel